Guselkumab, whether administered every 4 or 8 weeks, demonstrates “significant inhibition” of structural damage in patients ...

Federal budget cuts have created "a climate of anxiety" among medical researchers, says Maximilian F. Konig, a rheumatologist ...

Deucravacitinib met its primary endpoint of more than 20% improvement in ACR20 response among patients with psoriatic ...

Arthritis awareness emphasizes early detection of arthritis, a condition affecting joints, bones, and muscles. Recognizing ...

Psoriatic arthritis (PsA) patients who also qualified for a diagnosis of metabolic syndrome were far more likely to meet ...

Psoriatic disease is a long-term (chronic) disease with, thus far, no known cure. The good news, however, is that there are ...

Dr. Michael Garshick discusses recently published recommendations for cardiovascular risk screening for patients with ...

Sudden joint pain, or arthralgia, can stem from various causes, ranging from viral infections like the flu and COVID-19 to ...

New research emphasizes the importance of adequate-and possibly higher than currently recommended-protein intake for ...

Phase 1 data for Spyre Therapeutics, Inc.'s SPY002 & SPY072 show promise in autoimmune treatments. Advancing to Phase 2 ...

About one-third of psoriasis sufferers develop psoriatic arthritis, with swelling, tenderness and pain in joints, affecting daily activities and lifestyle. Psoriatic arthritis (PsA) is a chronic ...

Horsham: Johnson & Johnson is seeking the U.S. Food and Drug Administration (FDA) approval for the expansion of STELARA ...